Literature DB >> 28673014

The clinical characteristics of posterior reversible encephalopathy syndrome in patients with chronic renal failure.

Hongtao Hu1, Shen Xu1, Shuang Hu1, Weijia Xu1,2, Hua Shui1.   

Abstract

Few studies have investigated posterior reversible encephalopathy syndrome (PRES) in patients with chronic renal failure (CRF). The present study analyzed the clinical manifestations, laboratory examinations and imaging features of PRES in patients with CRF. A total of 42 patients with CRF with or without PRES were recruited in the current retrospective case-control study. Patient data taken prior to the onset of PRES in patients with CRF and PRES (n=21) were collected and analyzed. At the same time, data from patients with CRF but without PRES (n=21) were also analyzed. Brain magnetic resonance imaging (MRI) scans were collected from patients in the PRES group. The mean blood pressure of patients in the PRES group was significantly higher than that of the control group (systolic blood pressure: 172±15 mmHg vs. 135±14 mmHg, P<0.01; diastolic blood pressure: 95±16 mmHg vs. 64±13 mmHg, P<0.01). Furthermore, compared with the control group, mean serum albumin (Alb) and hemoglobin (Hb) concentrations in the PRES group were significantly lower (Alb: 29.1±5.3 g/l vs. 34.6±6.1 g/l, P=0.001; Hb: 74±16 g/l vs. 89±28 g/l, P=0.037). By contrast, mean LDH concentration was significantly higher in the PRES group (LDH: 336±141 U/l vs. 235±89 U/l, P=0.004). In the PRES group, 24 h urine volume was significantly lower in the PRES group than in the control group (24 h urine volume: 651±520 ml vs. 982±518 ml, P=0.046). No significant differences in levels of serum potassium (4.5±0.6 mmol/l vs. 4.4±0.5 mmol/l, P=0.377), sodium (138.3±4.9 mmol/l vs. 139.0±6.8 mmol/l, P=0.325), calcium (2.0±0.24 mmol/l vs. 1.9±0.24 mmol/l, P=0.673), alanine aminotransferase; (24±14 U/l vs. 18±8 U/l, P=0.975); aspartate aminotransferase (29±11 U/l vs. 24±9 U/l, P=0.619) and uric acid (448±148 µmol/l vs. 378±116 µmol/l, P=0.599) were found between the two groups. PRES is a relatively common nervous system complication arising in patients with CRF. Certain biochemical markers, including Hb and Alb, may be associated with PRES. Diagnosing PRES is difficult as computed tomography (CT) brain scans may be normal and MRI scans, which are more sensitive than CT scans at diagnosing PRES, are not always performed in patients with CRF. Thus, brain MRI scans should be taken first in such patients when PRES is suspected.

Entities:  

Keywords:  biochemical tests; chronic renal failure; clinical manifestations; imageology; posterior reversible encephalopathy syndrome

Year:  2017        PMID: 28673014      PMCID: PMC5488738          DOI: 10.3892/etm.2017.4570

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  33 in total

1.  Posterior reversible encephalopathy syndrome in a patient with ANCA-associated vasculitis.

Authors:  Alexandra Gonzalez Fuentes; Ashwini Komarla; John I Gomez
Journal:  Rheumatol Int       Date:  2010-07-10       Impact factor: 2.631

2.  Effects of venous needle turbulence during ex vivo hemodialysis on endothelial morphology and nitric oxide formation.

Authors:  Thanh N Huynh; Balu K Chacko; Xinjun Teng; Brigitta C Brott; Michael Allon; Stacey S Kelpke; John A Thompson; Rakesh P Patel; Andreas S Anayiotos
Journal:  J Biomech       Date:  2006-12-11       Impact factor: 2.712

Review 3.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

4.  Posterior reversible encephalopathy syndrome in ANCA-associated vasculitis.

Authors:  Hong-Liang Zhang; Yi Yang; Jiang Wu
Journal:  Rheumatol Int       Date:  2011-07-15       Impact factor: 2.631

5.  Renal failure and posterior reversible encephalopathy syndrome in patients with thrombotic thrombocytopenic purpura.

Authors:  Tamika M Burrus; Jay Mandrekar; Eelco F M Wijdicks; Alejandro A Rabinstein
Journal:  Arch Neurol       Date:  2010-07

6.  Erythropoietin-associated hypertensive posterior leukoencephalopathy.

Authors:  N Delanty; C Vaughan; S Frucht; P Stubgen
Journal:  Neurology       Date:  1997-09       Impact factor: 9.910

7.  Clinical features of reversible posterior leukoencephalopathy syndrome in patients with systemic lupus erythematosus.

Authors:  Yuichiro Fujieda; Hiroshi Kataoka; Toshio Odani; Kotaro Otomo; Masaru Kato; Shinji Fukaya; Kenji Oku; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi; Takao Koike
Journal:  Mod Rheumatol       Date:  2011-01-12       Impact factor: 3.023

8.  Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma.

Authors:  Jamal Oulad Hadj; Rogier DEN Braven; Corrine Tillier; Hans M Schrijver; Henk M W Verheul; Hans J VAN DER Vliet
Journal:  Oncol Lett       Date:  2012-03-16       Impact factor: 2.967

9.  Hemodialysis acutely impairs endothelial function in children.

Authors:  Marc R Lilien; Hein A Koomans; Cornelis H Schröder
Journal:  Pediatr Nephrol       Date:  2004-12-31       Impact factor: 3.714

Review 10.  Hypertensive encephalopathy in patients with chronic renal failure caused by stopping antihypertensive agents: a report of two cases.

Authors:  Mari Nakabou; Tatsuya Kai; Tetsuya Maeshima; Ken Kanamasa
Journal:  Clin Exp Nephrol       Date:  2009-12-15       Impact factor: 2.801

View more
  2 in total

1.  Central-variant posterior reversible encephalopathy syndrome with bilateral corticospinal tract involvement: a case report.

Authors:  Ning Han; Zhanyong Sun; Chenguang Zhou; Yaoyao Shen; Guanqing Li; Jianhua Wang
Journal:  Acta Neurol Belg       Date:  2020-07-15       Impact factor: 2.396

2.  Posterior reversible encephalopathy syndrome due to unilateral renal artery stenosis: A case report.

Authors:  Denis Babici; Fawzi Hindi; Khalid A Hanafy
Journal:  Brain Circ       Date:  2022-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.